{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T23:46:00Z","timestamp":1768175160312,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12149-025-02101-z","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T18:17:54Z","timestamp":1756145874000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of previous 177Lu-DOTATATE treatment on 90Y-microsphere treatment response in neuroendocrine tumor patients with liver metastasis"],"prefix":"10.1007","volume":"40","author":[{"given":"Fuad","family":"Aghazada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1868-3957","authenticated-orcid":false,"given":"Lebriz","family":"Uslu-Besli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Kibar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur Erdem","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nami","family":"Yeyin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eren","family":"Ertek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Bas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haluk Burcak","family":"Sayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"5","key":"2101_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000480383","volume":"33","author":"ST Lee","year":"2017","unstructured":"Lee ST, Kulkarni HR, Singh A, Baum RP. Theranostics of neuroendocrine tumors. Visc Med. 2017;33(5):358\u201366.","journal-title":"Visc Med"},{"issue":"1","key":"2101_CR2","volume":"2012","author":"R Basuroy","year":"2012","unstructured":"Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol. 2012;2012(1): 819193.","journal-title":"Int J Hepatol"},{"key":"2101_CR3","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10613","author":"O Popa","year":"2021","unstructured":"Popa O, Taban S, Pantea S, Plopeanu A, Barna R, Cornianu M, et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med. 2021. https:\/\/doi.org\/10.3892\/etm.2021.10613.","journal-title":"Exp Ther Med"},{"key":"2101_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cct.2016.08.001","volume":"50","author":"KY Fan","year":"2016","unstructured":"Fan KY, Wild AT, Halappa VG, Kumar R, Ellsworth S, Ziegler M, et al. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials. 2016;50:143\u20139.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"2101_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/COC.0b013e3181ec60b8","volume":"35","author":"A Kennedy","year":"2012","unstructured":"Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization (90Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. Am J Clin Oncol. 2012;35(1):81\u201390.","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"2101_CR6","first-page":"534","volume":"28","author":"C Turkmen","year":"2013","unstructured":"Turkmen C, Ucar A, Poyanli A, Vatankulu B, Ozkan G, Basaran M, et al. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm. 2013;28(7):534\u201340.","journal-title":"Cancer Biother Radiopharm"},{"issue":"8","key":"2101_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","volume":"17","author":"R Salem","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251\u201378.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"2101_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1148\/rg.284075170","volume":"28","author":"MJ Steward","year":"2008","unstructured":"Steward MJ, Warbey VS, Malhotra A, Caplin ME, Buscombe JR, Yu D. Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics. 2008;28(4):1131\u201345.","journal-title":"Radiographics"},{"issue":"3","key":"2101_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105(3):295\u2013309.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2101_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"key":"2101_CR11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","volume":"45","author":"U Garske-Rom\u00e1n","year":"2018","unstructured":"Garske-Rom\u00e1n U, Sandstr\u00f6m M, Fr\u00f6ss Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2101_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.critrevonc.2011.01.012","volume":"80","author":"V Goffredo","year":"2011","unstructured":"Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999\u20132009). Crit Rev Oncol Hematol. 2011;80(3):393\u2013410.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2101_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56\u201373.","journal-title":"Eur J Cancer"},{"issue":"10446","key":"2101_CR14","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet [Internet]. 2024;403(10446):2807\u201317.","journal-title":"The Lancet [Internet]."},{"key":"2101_CR15","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00259-011-1812-2","volume":"38","author":"F Giammarile","year":"2011","unstructured":"Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38:1393\u2013406.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2101_CR16","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","volume":"53","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, et al. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53(11):1663\u20139.","journal-title":"J Nucl Med"},{"issue":"5","key":"2101_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050962","volume":"13","author":"U Jahn","year":"2021","unstructured":"Jahn U, Ilan E, Sandstr\u00f6m M, Lubberink M, Garske-Rom\u00e1n U, Sundin A. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms. Cancers (Basel). 2021;13(5): 962.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2101_CR18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1021\/bc300103t","volume":"23","author":"D Mueller","year":"2012","unstructured":"Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WAP. Simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem. 2012;23(8):1712\u20137.","journal-title":"Bioconjug Chem"},{"key":"2101_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"JJ Zaknun","year":"2013","unstructured":"Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, H\u00f6rsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"2101_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143581","volume":"15","author":"M Weber","year":"2023","unstructured":"Weber M, Telli T, Kersting D, Seifert R. Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors. Cancers (Basel). 2023;15(14): 3581.","journal-title":"Cancers (Basel)"},{"key":"2101_CR21","unstructured":"(NCI) NCI. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. 2009."},{"key":"2101_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/978-3-031-56968-5_27","volume-title":"Neuroendocrine tumours: diagnosis and management","author":"M Ronot","year":"2024","unstructured":"Ronot M, Dioguardi Burgio M, Raynaus L, Paulatto L, Garzelli L, Gregory J, et al. Liver-directed therapies in neuroendocrine tumors. In: Neuroendocrine tumours: diagnosis and management. Springer; 2024. p. 575\u201393."},{"issue":"12","key":"2101_CR23","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/MNM.0000000000001284","volume":"41","author":"E Yilmaz","year":"2020","unstructured":"Yilmaz E, Engin MN, \u00d6zkan ZG, Kovan B, B\u00fcy\u00fckkaya F, Poyanli A, et al. Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not? Nucl Med Commun. 2020;41(12):1242\u20139.","journal-title":"Nucl Med Commun"},{"issue":"10","key":"2101_CR24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, et al. Quantitative 68Ga-DOTATATE PET\/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE. J Nucl Med. 2021;62(10):1406\u201314.","journal-title":"J Nucl Med"},{"key":"2101_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68 Ga] DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17:313\u20138.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"2101_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030592","volume":"14","author":"R Durmo","year":"2022","unstructured":"Durmo R, Filice A, Fioroni F, Cervati V, Finocchiaro D, Coruzzi C, et al. Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET\/CT parameters in metastatic advanced neuroendocrine tumor patients treated with PRRT. Cancers (Basel). 2022;14(3): 592.","journal-title":"Cancers (Basel)"},{"key":"2101_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00270-017-1871-2","volume":"41","author":"P Reimer","year":"2018","unstructured":"Reimer P, Virarkar MK, Binnenhei M, Justinger M, Sch\u00f6n MR, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-na\u00efve patients. Cardiovasc Intervent Radiol. 2018;41:744\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"2101_CR28","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biomedicines12071432","volume":"12","author":"N Bajestani","year":"2024","unstructured":"Bajestani N, Wu G, Hussein A, Makary MS. Examining the efficacy and safety of combined locoregional therapy and immunotherapy in treating hepatocellular carcinoma. Biomedicines. 2024;12(7):1432.","journal-title":"Biomedicines"},{"key":"2101_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1155\/2020\/5104082","volume":"2020","author":"ES Tsang","year":"2020","unstructured":"Tsang ES, Loree JM, Davies JM, Gill S, Liu D, Ho S, et al. Efficacy and prognostic factors for Y-90 radioembolization (Y-90) in metastatic neuroendocrine tumors with liver metastases. Can J Gastroenterol Hepatol. 2020;2020:8\u201312.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2101_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","volume":"100","author":"Z Jia","year":"2018","unstructured":"Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol [Internet]. 2018;100:23\u20139. https:\/\/doi.org\/10.1016\/j.ejrad.2018.01.012.","journal-title":"Eur J Radiol [Internet]."},{"issue":"12","key":"2101_CR31","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1097\/01.RVI.0000184594.01661.81","volume":"16","author":"R Salem","year":"2005","unstructured":"Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16(12):1627\u201339.","journal-title":"J Vasc Interv Radiol"},{"key":"2101_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-018-0224-9","volume":"5","author":"M Del Prete","year":"2018","unstructured":"Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, et al. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177 Lu-octreotate PRRT. EJNMMI Phys. 2018;5:1\u201320.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"2101_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40658-022-00436-4","volume":"9","author":"JC Malcolm","year":"2022","unstructured":"Malcolm JC, Falzone N, Gains JE, Aldridge MD, Mirando D, Lee BQ, et al. Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu] Lu-DOTATATE. EJNMMI Phys. 2022;9(1):24.","journal-title":"EJNMMI Phys"},{"key":"2101_CR34","unstructured":"Ertek E, Bas A. Evaluation of tumor vascularization in patients with neuroendocrine tumor liver metastasis receiving Y-90 radioembolization treatment after Lu-177 peptide receptor therapy. Cerrahpa\u015fa University, Radiology Department, Specialty Thesis. 2023. Available from: https:\/\/tez.yok.gov.tr\/UlusalTezMerkezi\/tezSorguSonucYeni.jsp"},{"key":"2101_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00259-013-2675-5","volume":"41","author":"H Ahmadzadehfar","year":"2014","unstructured":"Ahmadzadehfar H, Duan H, Haug AR, Walrand S, Hoffmann M. The role of SPECT\/CT in radioembolization of liver tumours. Eur J Nucl Med Mol Imaging. 2014;41:115\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2101_CR36","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s00259-021-05188-4","volume":"48","author":"H Duan","year":"2021","unstructured":"Duan H, Khalaf MH, Ferri V, Baratto L, Srinivas SM, Sze DY, et al. High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET\/CT scanner. Eur J Nucl Med Mol Imaging. 2021;48:2426\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02101-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:07:50Z","timestamp":1768165670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02101-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02101-z","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}